Home > News > Headline News > Archive

Click on title to read the full article.

The manly side of a woman's disease

September 23, 2010

By Andrea Markowitz, Chicago Tribune

Low awareness that men can get breast cancer may result in delayed treatment and poorer outcomes.

Val Lucier is a male breast cancer survivor. He considers himself lucky that he detected his cancer at Stage 3B — an advanced stage in which cancer has spread into lymph nodes, and at which a patient's chance of surviving the cancer five years from the time of diagnosis is 41 percent, according to the American Cancer Society.

Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells

September 18, 2010

By INTERNATIONAL JOURNAL OF ONCOLOGY 37: 1529-1536, 2010

Abstract. Mushrooms are an integral part of Traditional Chinese Medicine (TCM), and have been used for millennia to prevent or treat a variety of diseases. Currently mushrooms or their extracts are used globally in the form of dietary supplements. In the present study we have evaluated the anticancer effects of the dietary supplement

Genentech Provides Update on Avastin for Advanced Breast Cancer

September 17, 2010

By Genentech Press Release

South San Francisco, Calif. — September 17, 2010 — Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment. In accordance with FDA guidelines, the agency has extended the review period for the sBLAs by an additional 90 days. The company now anticipates FDA action on the sBLAs by December 17, 2010

FDA Approves High-Dose Fulvestrant for Refractory Metastatic Breast Cancer

September 17, 2010

By Yael Waknine, Medscape Infectious Diseases

The US Food and Drug Administration (FDA) has approved a 500-mg dose of fulvestrant intramuscular injection (Faslodex; AstraZeneca) for the treatment of hormone receptor–positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Genentech Breast Cancer Drug Denied Accelerated Approval

September 9, 2010

By FDA News

Genentech has been denied accelerated approval for its investigational breast cancer treatment trastuzumab-DM1 (T-DM1), a move likely to push the drug’s potential market entry back at least two years. The FDA issued a refuse-to-file letter for the BLA for T-DM1, a combination of Genentech’s Herceptin (trastuzumab) and ImmunoGen’s cancer-killing agent DM1, because all available treatment options for metastatic breast cancer were not exhausted